Download PDF
Semin Liver Dis 2015; 35(03): 236-249
DOI: 10.1055/s-0035-1562944
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander

Ester Vanni
1   Department of Medical Sciences, Division of Gastro-Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
,
Andrea Marengo
1   Department of Medical Sciences, Division of Gastro-Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
,
Lavinia Mezzabotta
1   Department of Medical Sciences, Division of Gastro-Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
,
Elisabetta Bugianesi
1   Department of Medical Sciences, Division of Gastro-Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

    Permissions and Reprints

Abstract

The top three leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD) in descending order are cardiovascular disease, cancer, and liver disease. It is clear now that the increased risk of metabolic and macro- and microvascular complications in NAFLD stems from the associated features of metabolic syndrome. However, NAFLD itself may contribute to the spectrum of risk factors associated with insulin resistance. The primary focus of this review is to summarize the main systemic associations of NAFLD, as well as to discuss the mechanisms that link them to NAFLD. Hepatic lipid accumulation in NAFLD impairs hepatic glucose and lipid metabolism further increasing the risk of type 2 diabetes mellitus and of cardiovascular disease, independently of established risk factors. The incidence, prevalence, and severity of these complications are proportional to the histological severity of liver damage suggesting that NAFLD, but particularly nonalcoholic steatohepatitis, can also contribute to the low-grade inflammatory state through the systemic release of several markers of inflammation, oxidative stress, and of procoagulant factors. The clinical implication of these findings is that patients with NAFLD require a multidisciplinary evaluation, with a major focus on type 2 diabetes mellitus and cardiovascular disease complications and may benefit from more intensive surveillance and early treatment interventions to decrease the risk for cardiovascular and kidney complications.

Keywords

nonalcoholic fatty liver disease - metabolic syndrome - cardiovascular disease - type 2 diabetes mellitus - colorectal cancer - chronic kidney disease
 

  • References

  • 1 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16) 1221-1231
    CrossrefPubMedGoogle Scholar
  • 2 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42 (5) 987-1000
    CrossrefPubMedGoogle Scholar
  • 3 Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care 2009; 32 (Suppl. 02) S164-S167
    CrossrefPubMedGoogle Scholar
  • 4 Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51 (6) 931-938
    CrossrefPubMedGoogle Scholar
  • 5 Simmons RK, Alberti KG, Gale EA , et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53 (4) 600-605
    CrossrefPubMedGoogle Scholar
  • 6 Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 7 Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM , et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87 (7) 3023-3028
    CrossrefPubMedGoogle Scholar
  • 8 Browning JD, Szczepaniak LS, Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6) 1387-1395
    CrossrefPubMedGoogle Scholar
  • 9 Ricci C, Longo R, Gioulis E , et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27 (1) 108-113
    CrossrefPubMedGoogle Scholar
  • 10 Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32 (4) 741-750
    CrossrefPubMedGoogle Scholar
  • 11 Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57 (4) 1378-1383
    CrossrefPubMedGoogle Scholar
  • 12 Balkau B, Lange C, Vol S, Fumeron F, Bonnet F ; Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56
    CrossrefPubMedGoogle Scholar
  • 13 Ryysy L, Häkkinen A-M, Goto T , et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49 (5) 749-758
    CrossrefPubMedGoogle Scholar
  • 14 de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22 (5) 756-761
    CrossrefPubMedGoogle Scholar
  • 15 Ekstedt M, Franzén LE, Mathiesen UL , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (4) 865-873
    CrossrefPubMedGoogle Scholar
  • 16 Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003; 13 (1) 15-21
    CrossrefPubMedGoogle Scholar
  • 17 Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22 (7) 1086-1091
    CrossrefPubMedGoogle Scholar
  • 18 Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30 (11) 2940-2944
    CrossrefPubMedGoogle Scholar
  • 19 Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25 (4) 476-481
    CrossrefPubMedGoogle Scholar
  • 20 Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25 (2) 352-356
    CrossrefPubMedGoogle Scholar
  • 21 Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35 (4) 717-722
    CrossrefPubMedGoogle Scholar
  • 22 Bae JC, Rhee EJ, Lee WY , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34 (3) 727-729
    CrossrefPubMedGoogle Scholar
  • 23 Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98 (9) 3637-3643
    CrossrefPubMedGoogle Scholar
  • 24 Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013; 108 (12) 1861-1868
    CrossrefPubMedGoogle Scholar
  • 25 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363 (14) 1341-1350
    CrossrefPubMedGoogle Scholar
  • 26 Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134 (2) 424-431
    CrossrefPubMedGoogle Scholar
  • 27 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115 (5) 1343-1351
    CrossrefPubMedGoogle Scholar
  • 28 Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia 2013; 56 (4) 746-757
    CrossrefPubMedGoogle Scholar
  • 29 Bugianesi E, Gastaldelli A, Vanni E , et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48 (4) 634-642
    CrossrefPubMedGoogle Scholar
  • 30 Siddiqui MS, Sterling RK, Luketic VA , et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013; 145 (6) 1271-9.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 31 Oni ET, Agatston AS, Blaha MJ , et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013; 230 (2) 258-267
    CrossrefPubMedGoogle Scholar
  • 32 Gastaldelli A, Kozakova M, Højlund K , et al; RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49 (5) 1537-1544
    CrossrefPubMedGoogle Scholar
  • 33 Moon SH, Noh TS, Cho YS , et al. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Angiology 2015; 66 (5) 472-480
    CrossrefPubMedGoogle Scholar
  • 34 Targher G, Bertolini L, Padovani R , et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30 (5) 1212-1218
    CrossrefPubMedGoogle Scholar
  • 35 Wong VW, Wong GL, Yip GW , et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60 (12) 1721-1727
    CrossrefPubMedGoogle Scholar
  • 36 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10 (6) 330-344
    CrossrefPubMedGoogle Scholar
  • 37 Schindhelm RK, Dekker JM, Nijpels G , et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191 (2) 391-396
    CrossrefPubMedGoogle Scholar
  • 38 Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27 (12) 2729-2735
    CrossrefPubMedGoogle Scholar
  • 39 Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10 (6) 646-650
    CrossrefPubMedGoogle Scholar
  • 40 Lazo M, Hernaez R, Bonekamp S , et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891
    CrossrefPubMedGoogle Scholar
  • 41 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (4) 1357-1365
    CrossrefPubMedGoogle Scholar
  • 42 Söderberg C, Stål P, Askling J , et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (2) 595-602
    CrossrefPubMedGoogle Scholar
  • 43 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 44 Dam-Larsen S, Franzmann M, Andersen IB , et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53 (5) 750-755
    CrossrefPubMedGoogle Scholar
  • 45 Adams LA, Lymp JF, St Sauver J , et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (1) 113-121
    CrossrefPubMedGoogle Scholar
  • 46 Rafiq N, Bai C, Fang Y , et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7 (2) 234-238
    CrossrefPubMedGoogle Scholar
  • 47 Hamaguchi M, Kojima T, Takeda N , et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13 (10) 1579-1584
    CrossrefPubMedGoogle Scholar
  • 48 Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum γ-glutamyl transpeptidase levels. Hepatology 2009; 50 (5) 1403-1411
    CrossrefPubMedGoogle Scholar
  • 49 Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13 (3) 153-160
    CrossrefPubMedGoogle Scholar
  • 50 Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: are they coupled?. Heart Fail Clin 2012; 8 (4) 663-670
    CrossrefPubMedGoogle Scholar
  • 51 Lautamäki R, Borra R, Iozzo P , et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 291 (2) E282-E290
    CrossrefPubMedGoogle Scholar
  • 52 Rijzewijk LJ, Jonker JT, van der Meer RW , et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010; 56 (3) 225-233
    CrossrefPubMedGoogle Scholar
  • 53 Kim NH, Park J, Kim SH , et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100 (12) 938-943
    CrossrefPubMedGoogle Scholar
  • 54 Perseghin G, Lattuada G, De Cobelli F , et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47 (1) 51-58
    PubMedGoogle Scholar
  • 55 Singh GK, Vitola BE, Holland MR , et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr 2013; 162 (6) 1160-1168 , 1168.e1
    CrossrefPubMedGoogle Scholar
  • 56 Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am J Cardiol 2013; 112 (3) 436-443
    CrossrefPubMedGoogle Scholar
  • 57 Fintini D, Chinali M, Cafiero G , et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 2014; 24 (1) 72-74
    CrossrefPubMedGoogle Scholar
  • 58 Pacifico L, Di Martino M, De Merulis A , et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014; 59 (2) 461-470
    CrossrefPubMedGoogle Scholar
  • 59 Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino Sr RB, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol 2010; 30 (9) 1855-1860
    CrossrefPubMedGoogle Scholar
  • 60 Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 2012; 32 (3) 830-835
    CrossrefPubMedGoogle Scholar
  • 61 Fragasso G, Perseghin G, De Cobelli F , et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27 (8) 942-948
    PubMedGoogle Scholar
  • 62 Matthew Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol 2013; 378 (1-2) 29-40
    CrossrefPubMedGoogle Scholar
  • 63 Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010; 20 (8) 583-590
    CrossrefPubMedGoogle Scholar
  • 64 Targher G, Bertolini L, Rodella S , et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51 (3) 444-450
    CrossrefPubMedGoogle Scholar
  • 65 Hwang ST, Cho YK, Yun JW , et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40 (6) 437-442
    CrossrefPubMedGoogle Scholar
  • 66 Li G, Shi W, Hug H, Chen Y, Liu L, Yin D. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb) 2012; 22 (1) 92-99
    PubMedGoogle Scholar
  • 67 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol 2012; 36 (5) 466-471
    CrossrefPubMedGoogle Scholar
  • 68 Ahn AL, Choi JK, Kim MN , et al. Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older. Korean J Fam Med 2013; 34 (3) 199-205
    CrossrefPubMedGoogle Scholar
  • 69 Li Y, Zhu S, Li B , et al. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol 2014; 46 (9) 1785-1791
    CrossrefPubMedGoogle Scholar
  • 70 Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5 (12) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 71 Yilmaz Y, Alahdab YO, Yonal O , et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010; 59 (9) 1327-1330
    CrossrefPubMedGoogle Scholar
  • 72 Yasui K, Sumida Y, Mori Y , et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60 (5) 735-739
    CrossrefPubMedGoogle Scholar
  • 73 Machado MV, Gonçalves S, Carepa F , et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012; 32 (2) 241-248
    CrossrefPubMedGoogle Scholar
  • 74 Chang Y, Ryu S, Sung E , et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57 (4) 569-576
    CrossrefPubMedGoogle Scholar
  • 75 Arase Y, Suzuki F, Kobayashi M , et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50 (10) 1081-1087
    CrossrefPubMedGoogle Scholar
  • 76 Targher G, Chonchol M, Bertolini L , et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19 (8) 1564-1570
    CrossrefPubMedGoogle Scholar
  • 77 Targher G, Mantovani A, Pichiri I , et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37 (6) 1729-1736
    CrossrefPubMedGoogle Scholar
  • 78 Musso G, Gambino R, Tabibian JH , et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11 (7) e1001680
    CrossrefPubMedGoogle Scholar
  • 79 Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43 (8) 617-649
    CrossrefPubMedGoogle Scholar
  • 80 Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut 2011; 60 (6) 745-746
    CrossrefPubMedGoogle Scholar
  • 81 Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010; 51 (2) 373-375
    CrossrefPubMedGoogle Scholar
  • 82 Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol 2012; 27 (1) 91-95
    CrossrefPubMedGoogle Scholar
  • 83 Wong VWS, Wong GLH, Tsang SWC , et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60 (6) 829-836
    CrossrefPubMedGoogle Scholar
  • 84 Huang KW, Leu HB, Wang YJ , et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis 2013; 15 (7) 830-835
    CrossrefPubMedGoogle Scholar
  • 85 Stadlmayr A, Aigner E, Steger B , et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med 2011; 270 (1) 41-49
    CrossrefPubMedGoogle Scholar
  • 86 Touzin NT, Bush KNV, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2011; 4 (3) 169-176
    CrossrefPubMedGoogle Scholar
  • 87 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology 2004; 40 (1) 46-54
    CrossrefPubMedGoogle Scholar
  • 88 Kim AY, Lee YS, Kim KH , et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010; 24 (7) 1441-1452
    CrossrefPubMedGoogle Scholar
  • 89 Bråkenhielm E, Veitonmäki N, Cao R , et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004; 101 (8) 2476-2481
    CrossrefPubMedGoogle Scholar
  • 90 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116 (7) 1793-1801
    CrossrefPubMedGoogle Scholar
  • 91 Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89 (2) 447-452
    CrossrefPubMedGoogle Scholar
  • 92 Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10 (11) 637-644
    CrossrefPubMedGoogle Scholar
  • 93 Henao-Mejia J, Elinav E, Jin C , et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482 (7384) 179-185
    PubMedGoogle Scholar
  • 94 Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12 (10) 661-672
    CrossrefPubMedGoogle Scholar
  • 95 Amar J, Burcelin R, Ruidavets JB , et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87 (5) 1219-1223
    PubMedGoogle Scholar
  • 96 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59 (3) 1174-1197
    CrossrefPubMedGoogle Scholar
  • 97 Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20 (26) 8351-8363
    CrossrefPubMedGoogle Scholar
  • 98 Hossain N, Stepanova M, Afendy A , et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011; 46 (4) 479-484
    PubMedGoogle Scholar
  • 99 Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ. Metabolic syndrome and gallstone disease. World J Gastroenterol 2012; 18 (31) 4215-4220
    CrossrefPubMedGoogle Scholar
  • 100 Chiu HM, Lin JT, Shun CT , et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007; 5 (2) 221-229 , quiz 141
    CrossrefPubMedGoogle Scholar
  • 101 Athyros VG, Tziomalos K, Gossios TD , et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376 (9756) 1916-1922
    CrossrefPubMedGoogle Scholar